Literature DB >> 34357593

Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial.

Yohannes W Woldeamanuel1, Douglas W Blayney2, Booil Jo3, Sophie E Fisher4, Catherine Benedict3, Ingrid Oakley-Girvan5,6,7, Shelli R Kesler8, Oxana Palesh2,4.   

Abstract

BACKGROUND: Breast cancer survivors often have persisting headache. In a secondary analysis of the Brief Behavioral Therapy for Cancer-Related Insomnia (BBT-CI) clinical trial (ClinicalTrials.gov identifier NCT02165839), the authors examined the effects of BBT-CI on headache outcomes in patients with breast cancer.
METHODS: Patients with breast cancer who were receiving chemotherapy were randomly assigned to receive either the BBT-CI intervention or the Healthy EAting Education Learning for healthy sleep (HEAL) control intervention, and both were delivered over 6 weeks by trained staff. Headache outcomes and heart rate variability (HRV) were measured at baseline, 6 weeks, 6 months, and 12 months. Mixed-effects models were used to examine longitudinal headache outcomes in the groups according to the intention to treat. Principal component analysis and agglomerative hierarchical clustering were conducted to reduce 16 variables for data-driven phenotyping.
RESULTS: Patients in the BBT-CI arm (n = 73) exhibited a significant reduction in headache burden over time (P = .02; effect size [Cohen d] = 0.43), whereas the reduction was not significant among those in the HEAL arm (n = 66). The first principal component was positively loaded by headache, sleep, fatigue, and nausea/vomiting and was negatively loaded by cognitive, physical, and emotional functioning. Agglomerative hierarchical clustering revealed 3 natural clusters. Cluster I (n = 58) featured the highest burden of headache, insomnia, and nausea/vomiting; cluster II (n = 50) featured the lowest HRV despite a low burden of headache and insomnia; and cluster III (n = 31) showed an inverse relation between HRV and headache-insomnia, signifying autonomic dysfunction.
CONCLUSIONS: BBT-CI is efficacious in reducing headache burden in breast cancer survivors. Patient phenotyping demonstrates a headache type featuring sleep disturbance, nausea/vomiting, and low physical functioning-revealing similarities to migraine. LAY
SUMMARY: Breast cancer survivors often have persisting headache symptoms. In patients with cancer, treatment of chronic headache disorders using daily medications may be challenging because of drug interactions with chemotherapy and other cancer therapies as well as patients' reluctance to add more drugs to their medicine list. Headache and sleep disorders are closely related to each other. This study demonstrates that a sleep behavioral therapy reduced headache burden in breast cancer survivors. In addition, the majority of headache sufferers had a headache type with similarities to migraine-featuring sleep disturbance, nausea/vomiting, and low physical functioning.
© 2021 American Cancer Society.

Entities:  

Keywords:  behavior therapy; breast neoplasms; clinical trial; headache; sleep initiation and maintenance disorders

Mesh:

Year:  2021        PMID: 34357593      PMCID: PMC8578351          DOI: 10.1002/cncr.33844

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  60 in total

1.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials.

Authors:  Kenneth F Schulz; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2010-03-24       Impact factor: 25.391

2.  The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

Authors:  M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

Review 3.  Serotonin control of sleep-wake behavior.

Authors:  Jaime M Monti
Journal:  Sleep Med Rev       Date:  2011-04-02       Impact factor: 11.609

4.  Individuals with tension and migraine headaches exhibit increased heart rate variability during post-stress mindfulness meditation practice but a decrease during a post-stress control condition - A randomized, controlled experiment.

Authors:  Muhammad Abid Azam; Joel Katz; Vina Mohabir; Paul Ritvo
Journal:  Int J Psychophysiol       Date:  2016-10-18       Impact factor: 2.997

Review 5.  The global burden of headache: a documentation of headache prevalence and disability worldwide.

Authors:  Lj Stovner; K Hagen; R Jensen; Z Katsarava; Rb Lipton; Ai Scher; Tj Steiner; J-A Zwart
Journal:  Cephalalgia       Date:  2007-03       Impact factor: 6.292

6.  An excitement subscale of the Positive and Negative Syndrome Scale.

Authors:  Jean-Pierre Lindenmayer; Eileen Brown; Robert W Baker; Leslie M Schuh; Lixin Shao; Mauricio Tohen; Saeeduddin Ahmed; Virginia L Stauffer
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

7.  Validation of single-item linear analog scale assessment of quality of life in neuro-oncology patients.

Authors:  Dona E C Locke; Paul A Decker; Jeff A Sloan; Paul D Brown; James F Malec; Matthew M Clark; Teresa A Rummans; Karla V Ballman; Paul L Schaefer; Jan C Buckner
Journal:  J Pain Symptom Manage       Date:  2007-08-20       Impact factor: 3.612

Review 8.  Serotonin and migraine: biology and clinical implications.

Authors:  E Hamel
Journal:  Cephalalgia       Date:  2007-11       Impact factor: 6.292

Review 9.  Hidden Signals-The History and Methods of Heart Rate Variability.

Authors:  Gernot Ernst
Journal:  Front Public Health       Date:  2017-10-16

10.  Autonomic adaptations mediate the effect of hydration on brain functioning and mood: Evidence from two randomized controlled trials.

Authors:  Hayley A Young; Alecia Cousins; Stephen Johnston; John M Fletcher; David Benton
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.